NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date (Descending) | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
72789-0393-30 | 72789-0393 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 17, 2024 | In Use | |
00069-0252-30 | 00069-0252 | Talazoparib | Talzenna | 0.1 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | April 17, 2024 | In Use | |
00069-0353-30 | 00069-0353 | Talazoparib | Talzenna | 0.25 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | April 17, 2024 | In Use | |
00069-0454-30 | 00069-0454 | Talazoparib | Talzenna | 0.35 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | April 17, 2024 | In Use | |
00069-0546-30 | 00069-0546 | Talazoparib | Talzenna | 0.5 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | April 17, 2024 | In Use | |
00069-0655-30 | 00069-0655 | Talazoparib | Talzenna | 0.75 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | April 17, 2024 | In Use | |
00069-0757-30 | 00069-0757 | Talazoparib | Talzenna | 1.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | April 17, 2024 | In Use | |
75907-0095-40 | 75907-0095 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | April 15, 2024 | In Use | |
70771-1699-01 | 70771-1699 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 15, 2024 | In Use | |
70771-1700-01 | 70771-1700 | Dexamethasone | Dexamethasone | 6.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 15, 2024 | In Use | |
70771-1701-01 | 70771-1701 | Dexamethasone | Dexamethasone | 2.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 15, 2024 | In Use | |
70771-1704-01 | 70771-1704 | Dexamethasone | Dexamethasone | 0.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 15, 2024 | In Use | |
70771-1705-01 | 70771-1705 | Dexamethasone | Dexamethasone | 0.75 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 15, 2024 | In Use | |
70771-1707-01 | 70771-1707 | Dexamethasone | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 15, 2024 | In Use | |
72578-0167-01 | 72578-0167 | Dexamethasone | Dexamethasone | 2.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 15, 2024 | In Use | |
72578-0168-01 | 72578-0168 | Dexamethasone | Dexamethasone | 0.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 15, 2024 | In Use | |
72578-0169-01 | 72578-0169 | Dexamethasone | Dexamethasone | 0.75 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 15, 2024 | In Use | |
72578-0170-01 | 72578-0170 | Dexamethasone | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 15, 2024 | In Use | |
72578-0171-01 | 72578-0171 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 15, 2024 | In Use | |
72578-0172-01 | 72578-0172 | Dexamethasone | Dexamethasone | 6.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 15, 2024 | In Use | |
70518-0948-03 | 70518-0948 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 15, 2024 | In Use | |
65862-0390-05 | 65862-0390 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 12, 2024 | In Use | |
65862-0391-02 | 65862-0391 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 12, 2024 | In Use | |
65862-0391-05 | 65862-0391 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 12, 2024 | In Use | |
00002-5340-60 | 00002-5340 | Selpercatinib | RETEVMO | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, RET | Oral | April 10, 2024 | In Use |
Found 10,000 results in 4 milliseconds — Export these results